181 related articles for article (PubMed ID: 21854084)
1. Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol.
Radwan FF; Zhang L; Hossain A; Doonan BP; God JM; Haque A
Leuk Lymphoma; 2012 Feb; 53(2):305-14. PubMed ID: 21854084
[TBL] [Abstract][Full Text] [Related]
2. Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.
Goldstein OG; Hajiaghamohseni LM; Amria S; Sundaram K; Reddy SV; Haque A
Cancer Immunol Immunother; 2008 Oct; 57(10):1461-70. PubMed ID: 18343923
[TBL] [Abstract][Full Text] [Related]
3. Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.
God JM; Cameron C; Figueroa J; Amria S; Hossain A; Kempkes B; Bornkamm GW; Stuart RK; Blum JS; Haque A
J Immunol; 2015 Feb; 194(4):1434-45. PubMed ID: 25595783
[TBL] [Abstract][Full Text] [Related]
4. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
[TBL] [Abstract][Full Text] [Related]
5. HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition.
Hossain A; God JM; Radwan FF; Amria S; Zhao D; Bethard JR; Haque A
Clin Dev Immunol; 2011; 2011():780839. PubMed ID: 22162713
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.
Zhao D; Amria S; Hossain A; Sundaram K; Komlosi P; Nagarkatti M; Haque A
Cell Immunol; 2011; 271(2):392-400. PubMed ID: 21903207
[TBL] [Abstract][Full Text] [Related]
7. HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition.
Amria S; Hajiaghamohseni LM; Harbeson C; Zhao D; Goldstein O; Blum JS; Haque A
Eur J Immunol; 2008 Jul; 38(7):1961-70. PubMed ID: 18506881
[TBL] [Abstract][Full Text] [Related]
8. Human leukocyte antigen-DO regulates surface presentation of human leukocyte antigen class II-restricted antigens on B cell malignancies.
Kremer AN; van der Meijden ED; Honders MW; Pont MJ; Goeman JJ; Falkenburg JH; Griffioen M
Biol Blood Marrow Transplant; 2014 May; 20(5):742-7. PubMed ID: 24530695
[TBL] [Abstract][Full Text] [Related]
9. In cutaneous T-cell lymphoma, class II MHC molecules on CD1+ antigen-presenting cells are upregulated in involved compared with uninvolved epidermis.
Hansen ER; Bang B; Larsen JK; Vejlsgaard GL; Baadsgaard O
Br J Dermatol; 1994 Dec; 131(6):780-8. PubMed ID: 7531998
[TBL] [Abstract][Full Text] [Related]
10. Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing.
Hershberg RM; Framson PE; Cho DH; Lee LY; Kovats S; Beitz J; Blum JS; Nepom GT
J Clin Invest; 1997 Jul; 100(1):204-15. PubMed ID: 9202073
[TBL] [Abstract][Full Text] [Related]
11. Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.
God JM; Zhao D; Cameron CA; Amria S; Bethard JR; Haque A
Immunology; 2014 Jul; 142(3):492-505. PubMed ID: 24628049
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis.
Lobo PI; Chang MY; Mellins E
Immunology; 1996 Aug; 88(4):625-9. PubMed ID: 8881767
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells.
Tomazin R; Boname J; Hegde NR; Lewinsohn DM; Altschuler Y; Jones TR; Cresswell P; Nelson JA; Riddell SR; Johnson DC
Nat Med; 1999 Sep; 5(9):1039-43. PubMed ID: 10470081
[TBL] [Abstract][Full Text] [Related]
14. Peptide Modification Diminishes HLA Class II-restricted CD4
Doonan BP; Amria S; Bethard JR; Banik NL; Hathaway-Schrader JD; Haque A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499557
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the MHC class II antigen presentation pathway by human cytomegalovirus.
Johnson DC; Hegde NR
Curr Top Microbiol Immunol; 2002; 269():101-15. PubMed ID: 12224504
[TBL] [Abstract][Full Text] [Related]
16. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
18. Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis.
Yoshino T; Cao L; Nishiuchi R; Matsuo Y; Yamadori I; Kondo E; Teramoto N; Hayashi K; Takahashi K; Kamikawaji N
Eur J Immunol; 1995 Aug; 25(8):2190-4. PubMed ID: 7545111
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells.
Costantino CM; Ploegh HL; Hafler DA
J Immunol; 2009 Jul; 183(2):945-52. PubMed ID: 19553543
[TBL] [Abstract][Full Text] [Related]
20. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
